Nevirapine uptake into the central nervous system of the guinea pig: An in situ brain perfusion study

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 2, 2006, Pages 746-751

  Gibbs, J E ^a   Gaffen, Z ^a   Thomas, S A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CARBON 14; EFAVIRENZ; MANNITOL; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRITIUM;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN; BRAIN CAPILLARY; BRAIN PERFUSION; CAROTID ARTERY; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CHOROID PLEXUS; CONTROLLED STUDY; DEMENTIA; DEPLETION; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DIFFUSION; DRUG PENETRATION; DRUG UPTAKE; EXPERIMENTAL MODEL; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; GUINEA PIGS; NEVIRAPINE; PERFUSION;

EID: 33645849551     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.098459     Document Type: Article

References (41)

1. Albright AV, Soldan SS, and Gonzalez-Scarano F (2003) Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol 9:222-227.
2. Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, and Khoo SH (2005) Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 78:132-142.
3. Anthonypillai C, Gibbs JE, and Thomas SA (2006) The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, cerebrospinal fluid and choroid plexuses. Cerebrospinal Fluid Res 3:1.
4. Anthonypillai C, Sanderson RN, Gibbs JE, and Thomas SA (2004) The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid and choroid plexuses of the guinea pig. J Pharmacol Exp Ther 308:912-920.
5. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, and Pomerantz RJ (1996) Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10:573-585.
6. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, and Gonzalez-Lahoz J (2000) Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14:807-812.
7. Carr A and Cooper DA (1996) Current clinical experience with nevirapine for HIV infection. Adv Exp Med Biol 394:299-304.
8. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, and Back D (2003) The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 33:551-556.
9. Chen H, Wood C, and Petito CK (2000) Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: potential role of choroid plexus in the pathogenesis of HIV encephalitis. J Neurovirol 6:498-506.
10. Collazos J (2003) Opportunistic infections of the CNS in patients with AIDS: diagnosis and management. CNS Drugs 17:869-887.
11. Drewes LR, Mies G, Hossmann KA, and Stocklin G (1987) Blood-brain transport and regional distribution of bromo-benzodiazepine. Brain Res 401:55-59.
12. Ghersi-Egea JF, Finnegan W, Chen JL, and Fenstermacher JD (1996) Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 75:1271-1288.
13. Gibbs JE and Thomas SA (2002) The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80:392-404.
14. Gibbs JE and Thomas SA (2005) Choroid plexus and drug therapy for AIDS encephalopathy, in The Blood-Cerebrospinal Fluid Barrier (Zheng WC and Chodobski A eds) pp 391-411, Taylor and Francis Books Ltd., London, UK.
15. Glynn SL and Yazdanian M (1998) In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 87:306-310.
16. Groothuis DR and Levy RM (1997) The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 3:387-400.
17. Gross PM (1992) Circumventricular organ capillaries. Prog Brain Res 91:219-233.
18. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
19. Hammer SM (2005) Single-dose nevirapine and drug resistance: the more you look, the more you find. J Infect Dis 192:1-3.
20. Hartmann M, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, and Petzoldt D (2005) Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). Int J STD AIDS 16:404-409.
21. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, et al. (2003) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868.
22. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, and Sacktor N (2003) Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 9:205-221.
23. Petito C (2004) Human immunodeficiency virus type 1 compartmentalization in the central nervous system. J Neurovirol 10:21-24.
24. Petito CK, Chen H, Mastri AR, Torres-Munoz J, Roberts B, and Wood C (1999) HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J Neurovirol 5:670-677.
25. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, and Grady PA (1985) Evidence for a "paravascular" fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 326:47-63.
26. Sabin CA (2002) The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS 16:S61-S68.
27. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, et al. (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142.
28. Sawchuk RJ and Yang Z (1999) Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 39:5-31.
29. Stormer E, von Moltke LL, Perloff MD, and Greenblatt DJ (2002) Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 19:1038-1045.
30. Taylor EM (2002) The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 41:81-92.
31. Thomas SA (2004) Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 10:1313-1324.
32. Thomas SA, Bye A, and Segal MB (2001) Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Ther 298:947-953.
33. Thomas SA and Segal MB (1998) The transport of the anti-HIV drug, 2′,3′-didehydro-3′-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers. Br J Pharmacol 125:49-54.
34. Triguero D, Buciak J, and Pardridge WM (1990) Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54:1882-1888.
35. Van Praag RM, van Weert EC, van Heeswijk RP, Zhou XJ, Sommadossi JP, Jurriaans S, Lange JM, Hoetelmans RM, and Prins JM (2002) Stable concentrations of zidovudine, stavudine, lamivudine, abacavir and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 46:896-899.
36. Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, et al. (2001a) The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 184:37-42.
37. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, and Hoetelmans RM (2001b) High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15:1089-1095.
38. Verweel G, Sharland M, Lyall H, Novelli V, Gibb DM, Dumont G, Ball C, Wilkins E, Walters S, and Tudor-Williams G (2003) Nevirapine use in HIV-1-infected children. AIDS 17:1639-1647.
39. von Giesen HJ, Koller H, Theisen A, and Arendt G (2002) Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr 29:363-367.
40. Williams KC and Hickey WF (2002) Central nervous system damage, monocytes and macrophages and neurological disorders in AIDS. Annu Rev Neurosci 25:537-562.
41. Wise ME, Mistry K, and Reid S (2002) Drug points: neuropsychiatric complications of nevirapine treatment. BMJ 324:879.